Table 4.
Summary of LSM mean rations for relative bioavailability of testosterone from TNG in the phase 1 PK study (90% CI in parentheses)
| Asymptomatic/symptomatic | Symptomatic untreated/treated with oxymetazoline | |
|---|---|---|
| n | 14 | 14 |
| Uncorrected baseline | ||
| AUC ratio | 1.03 (1.00,1.05) | 1.00 (0.98,1.02) |
| Cavg ratio | 1.04 (1.01,1.07) | 1.00 (0.97, 1.04) |
| Cmax ratio | 1.02 (0.99,1.06) | 1.01 (0.98,1.04) |
| Baseline corrected | ||
| AUC ratio | 1.03 (0.99, 1.08) | 1.00 (0.96, 1.05) |
| Cavg ratio | 1.05 (0.98, 1.13) | 1.01 (0.93, 1.08) |
| Cmax ratio | 1.01 (0.97, 1.05) | 1.01 (0.97, 1.05) |
AUC: area under the curve; CI: confidence interval; PK: pharmacokinetic; TNG: testosterone nasal gel.